Deutsches Herzzentrum der Charité
Berlin, State of Berlin, 13353, Germany
NCT Number: NCT03894033
The objective of this registry is to collect information on the performance and clinical benefits of the AMDS (Ascyrus Medical Dissection Stent) to treat patients with acute "DeBakey type I dissections" and with or without so called "preoperative clinically relevant malperfusion" and/or "intramural hematomas".
In a healthy aorta (the vessel that supplies blood to most of the body) the blood flows freely through the main lumen (a space inside the vessel where blood flows). The participants involved in this study have a tear that has separated the inner layer of the aorta wall and created a secondary channel (false lumen) in addition to the main channel (true lumen), and huts, the blood flows through both channels.
AMDS is a stent (a metal tube helping to keep the vessel open) that is placed in the descending thoracic aorta. AMDS is a medical device commercially available in the countries in which the study is being conducted and it is used as standard of care according to its indication.
This study is active but is not currently recruiting participants.
Notify Me18 year–80 year
All sexes
Observational
Berlin, State of Berlin, 13353, Germany
Observational, prospective and retrospective, non-randomized, non-interventional study to investigate the performance and clinical benefits of the AMDS to treat patients with acute DeBakey type I dissections with or without clinically relevant preoperative malperfusion and/or intramural hematomas (IMH).
Participating physicians will be asked to provide their observations collected during routine care for patients they had decided to treat with AMDS. Informed consent of the patients to allow the use of their clinical records for the purpose of this observational study will be obtained before data are being collected.
A total number of 300 subjects will be enrolled in up to 30 sites in Europe and Canada. The AMDS will be implanted according to the instructions for use and at the discretion of the treating physician.
This registry was initiated by Ascyrus Medical GmbH in August 2019 (DARTS PM Registry). About 70 patients were enrolled at that time by German and Canadian sites under previous protocol. The patient's enrollment was put on-hold and the study has been re-started as PROTECT Registry with updated study documents as per JOTEC's standard operating procedures upon Ethics Committees approvals.
Patients already included in DARTS PM Registry will be re-consented (where applicable as per local regulatory requirements) to allow the retrospective and prospective collection of additional data points not included in the initial version of the protocol. It is also planned to retrospectively include up to 150 subjects of the 300 targeted subjects, which have been treated with AMDS and who consent to the collection of their data (if required by national law) and are willing to continue in this registry, if applicable.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
General Exclusion Criteria:
Medical Exclusion Criteria:
Anatomical Exclusion Criteria:
The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
Other names: AMDS Arch Remodeling Therapy
Time frame: 3-6 months
Rate of patients with positive arch remodeling defined as either stable or decreasing total aortic diameter in zone 2.
Time frame: In-hospital, at 30 days, 3-6 months, 1 year, 2, 3, 4, 5 years
Rate of all-cause mortality
Time frame: Discharge (definition: between 1-29 days)
Rate of device-related in-hospital mortality
Time frame: 30 days, 3-6 months, 1 year, 2, 3, 4, 5 years
Rate of device-related mortality
Time frame: Discharge (definition: between 1-29 days), 30 days, and 3-6 months
Rate of patients with resolution of malperfusion in patients who presented initially with malperfusion
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years
Rate of patients with new disabling (mRS ≥ 2), permanent (>30 days) stroke
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years
Rate of patients with new disabling (mRS ≥ 2), transient (< 30 days) stroke
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years
Rate of patients with new paralysis
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years
Rate of patients with new paraplegia and 5 years
Time frame: 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years
Rate of patients with new aortic rupture associated with the implantation of the device (procedure or AMDS related)
Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with patent innominate artery (< 50% stenosis of the origin of the branch vessels)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Source of innominate artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)
Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with patent left carotid artery (< 50% stenosis of the origin of the branch vessels)
Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)
Source of left carotid artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)
Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with patent left subclavian artery (< 50% stenosis of the origin of the branch vessels)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Source of left subclavian artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)
Rate of patients with absence of distal anastomotic new entry tear (DANE)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)
Rate of patients with increasing true lumen [change in diameter at the maximal diameter location within each Zone which is greater than or equal to a 5 mm expansion in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)
Rate of patients with stable true lumen [change in diameter at the maximal diameter location within each Zone which is between a 5 mm reduction and a 5 mm expansion in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with stable or increasing true lumen in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with decreasing true lumen [change in diameter at the maximal diameter location within each Zone which is greater than or equal to a 5 mm reduction in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with increasing false lumen (≥ 5mm) in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with stable false lumen in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with decreasing false lumen (≤ - 5 mm) in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Stable or decreasing false lumen in the stented region (Zones 1-3)
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years
Rate of patients with freedom from AMDS stent removal
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years
Rate of patients with freedom from AMDS-related reintervention
Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years
Rate of patients with freedom from aortic arch reintervention
Time frame: Discharge (definition: between 1-29 days)
Rate of patients with successful AMDS deployment (at discharge
Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)
Rate of patients with completely thrombosed, partially thrombosed, or patent false lumen in the arch and descending aorta (Zones 0-5)
JOTEC GmbH
Industry
Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection: PROTECT Registry
Acronym: PROTECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04966247
Acute Aortic Syndrome, Aneurysm
London, United Kingdom
View Trial DetailsNCT07117825
Acute Aortic Syndrome, Aneurysm
Roma, Italy
View Trial DetailsNCT05659641
Acute Aortic Syndrome, Aneurysm
Hefei, Anhui, China
View Trial DetailsNCT05389865
Abnormalities, Multiple, Acute Aortic Syndrome
Glasgow, United Kingdom
View Trial Details